GLP-1 Agonists in Serious Mental Illness: Current Evidence

In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done?
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.
• Learn more about our membership here
• Earn 0.75 CMEs: Quick Take Vol. 84
• GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?